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Cardiovascular risk profile in patients treated with sirolimus
after renal transplantation. Renal transplant patients are inher-
ently predisposed to cardiovascular disease (CVD) as a result of
prolonged exposure to multiple cardiovascular risk factors. Ap-
proximately one half of all late graft losses are due to death with
a functioning graft, and CVD is the most frequent cause of death
with a functioning graft among these patients. Immunosuppres-
sive therapies associated with a reduced burden of risk for CVD
would therefore greatly decrease post-transplantation morbid-
ity and mortality. The nephrotoxic effects observed with the use
of calcineurin inhibitors (CNIs), such as cyclosporine (CsA),
run counter to the goal of renal transplant therapy. Sirolimus,
a more recent immunosuppressive agent with a unique mech-
anism of action, offers an alternative to CsA. Recent data
from a 4-year study investigating early CsA withdrawal from
a sirolimus-CsA-steroid (SRL-CsA-ST) combination demon-
strated significantly better renal function, lower blood pres-
sure, and improved graft survival after CsA withdrawal. Dur-
ing that trial, the increase in serum lipids induced by sirolimus
was generally manageable with lipid-lowering therapy. Fur-
ther investigation is warranted to evaluate the value of CNI-
free therapy compared with CNI-based regimens in reducing
cardiovascular risk factors and improving patient and graft
survival.
Advances in immunosuppressive therapy have con-
tributed to a marked decrease in acute rejection rates
following renal transplantation [1]. However, renal trans-
plant patients are more prone to cardiovascular disease
(CVD) compared with the general population, and CVD
remains the leading cause of death after kidney trans-
plantation. Cumulative records in the United States Re-
nal Data System (USRDS) from more than 68,000 first
kidney transplant patients from 1994 to 2000 show that
approximately 40% of patients die from CVD [2]. The
high prevalence and accumulation of cardiovascular risk
factors before and after transplantation contribute to the
high incidence of CVD. Foley et al have reported annual
mortality rates resulting from CVD in renal transplant
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patients and in the general population [3]. The 2 popu-
lations were matched by age, sex, and the presence of
diabetes. Across all age groups, the annual mortality rate
was higher in renal transplant recipients than in the gen-
eral population. The difference in risk was found to be
greater during the early years and tended to diminish
with age, as the rate of CVD mortality increased in the
general population.
Of the established cardiovascular risk factors,
hypertension, post-transplantation diabetes, and hy-
perlipidemia are more frequently associated with
immunosuppressive therapy, and are predictors of
chronic rejection [4]. Thus, cardiovascular risk man-
agement should consider selecting immunosuppressive
regimens that reduce the risk from indirect factors,
such as renal dysfunction and acute rejection [5, 6].
Agents that mitigate cardiovascular risk while providing
improved efficacy outcomes for renal transplant patients
would address this need, thereby reducing morbidity
and mortality in this population. This paper discusses
the emerging profile of sirolimus therapy in relation to
efficacy outcomes and cardiovascular risk factors.
PRECLINICAL DATA
Sirolimus, an mTOR inhibitor, is an immunosuppres-
sive agent with a unique mechanism of action [7, 8].
Sirolimus suppresses graft rejection by interfering with
cytoplasmic biochemical cascades that transduce signals
from the cell membrane to the nucleus. In animal mod-
els of organ transplantation, sirolimus exhibited potent
antirejection activity and the ability to prolong allo-
graft survival [8, 9]. Preclinical studies also indicated that
sirolimus has no deleterious effects on renal function
[10, 11]. Shihab et al [11] concluded that the combina-
tion of sirolimus and mycophenolate mofetil (MMF) was
particularly promising because it suppressed transform-
ing growth factor beta (TGF-b) and had no effect on
glomerular filtration.
In addition to the antagonism of immune cytokine-
mediated lymphocyte proliferation, sirolimus in-
hibits growth factor–stimulated smooth muscle cell
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proliferation and migration [12–15]. Sirolimus was
shown to reduce neointimal hyperplasia by its inhibitory
effect on arterial smooth muscle [16, 17]. Thus, sirolimus
demonstrates activity on both lymphoid and nonlym-
phoid cells [18]. Studies in a model of graft-versus-host
disease (GVD) showed that along with preventing
the progression of preexisting GVD, treatment with
sirolimus resulted in its partial regression [19]. Ad-
ditionally, despite elevating serum lipids, sirolimus
inhibited atherosclerosis in experimental mouse models
of atherogenesis [20, 21].
CLINICAL DATA
The success of sirolimus as prophylaxis for acute re-
nal transplant rejection when used concomitantly with
existing therapies has been confirmed in clinical studies.
Early studies included a phase 2 trial [22], and 2 phase
3 trials that compared a sirolimus/CsA combination with
azathioprine [23] or placebo [24]. These trials demon-
strated reduced acute rejection rates, but dose-dependent
increases in serum lipids and aminotransferases, and de-
creases in platelet and leukocyte counts were also ob-
served. Importantly, the phase 3 trials demonstrated that
sirolimus exacerbated the nephrotoxic effects of CsA.
Direct comparison of sirolimus versus CsA was car-
ried out by 2 early phase 2 studies conducted in Europe
[25–27]. Patients received either CsA or sirolimus in com-
bination therapy with corticosteroids and azathioprine or
corticosteroids and MMF. Sirolimus did not exhibit the
nephrotoxic properties of CsA, and renal function was
enhanced after CsA-free, sirolimus-based therapy. Using
the 2-year post-transplantation data from these studies, a
follow-up analysis was performed to evaluate the cardio-
vascular risk factors associated with sirolimus and CsA
[28]. A higher incidence of hypercholesterolemia and hy-
pertriglyceridemia was observed in the sirolimus group.
Fasting serum cholesterol and triglyceride levels peaked
at month 2, and declined through month 12, whereafter
levels stabilized. The decrease in triglyceride and choles-
terol levels in the sirolimus group from month 2 onward
coincided with the initiation of protocol-specified lower
sirolimus target trough levels, the tapering of steroid
doses, and the introduction of lipid-lowering therapy. The
2-year data continued to show favorable outcomes with
respect to risk factors, such as hypertension and renal
function, in response to sirolimus therapy as compared
with CsA therapy. No significant differences were seen
between the sirolimus- and CsA-based treatment groups
in the incidence of total diabetes and insulin-dependent
diabetes and in the frequency of death due to cardio-
vascular events. Thus, the benefits of decreased hyper-
tension and improved renal function were evident with
sirolimus therapy; however, poor lipid profiles were a side
effect that had to be managed with increased use of lipid-
lowering therapy.
A subsequent study by Flechner et al directly com-
paring sirolimus with CsA reported improved outcomes
by adding an induction agent and reducing the doses of
sirolimus to minimize side effects [29]. Their randomized
phase 2 trial employed basiliximab as an antilymphocyte
induction agent, and sirolimus or CsA in addition to MMF
and steroids in primary renal allograft recipients. The re-
sults showed comparable outcomes for patient survival,
graft survival, and biopsy-confirmed acute rejection, and
significantly better renal function in sirolimus-treated pa-
tients. Fasting lipid levels, although higher when com-
pared with baseline, were similar in both the sirolimus
and CsA groups at all intervals studied in the 1-year pe-
riod. Thus, a sirolimus-based regimen without CsA was
found to confer significant renal function advantages,
thereby potentially alleviating the risk of chronic allo-
graft nephropathy.
Recognizing the value of obtaining lower acute re-
jection rates while reducing the nephrotoxicity associ-
ated with the CsA and preserving the sirolimus-related
cardiovascular benefits of lower hypertension and im-
proved renal function, a phase 2 study evaluated whether
renal function could be further improved by eliminat-
ing CsA from a sirolimus-CsA regimen [30]. This study
investigated a regimen of full-dose CsA (microemul-
sion) plus fixed-dose sirolimus (2 mg/day, solution
formulation) versus CsA withdrawal plus concentration-
controlled sirolimus (trough levels 10 to 20 ng/mL). All
patients also received corticosteroids. At 12 months af-
ter transplantation, renal function was significantly better
in the CsA elimination group. The incidence of hyper-
tension, edema, hypomagnesemia, and dyspnea was also
significantly lower in these patients. Comparison of the
full-dose CsA group with the CsA-withdrawal group re-
vealed significantly lower serum creatinine levels and sig-
nificantly higher glomerular filtration rates (GFR) in the
latter. The CsA-withdrawal group, however, used higher
doses of sirolimus, and was associated with higher rates of
abnormal liver function tests, diarrhea, hypokalemia, and
thrombocytopenia. Graft and patient survival rates were
similar in the 2 groups. Thus, concentration-controlled
sirolimus with early withdrawal of CsA resulted in im-
proved renal function without a significant increase in
the number of acute rejection episodes.
Nearly concurrent with the above-mentioned phase
2 trial, a phase 3 trial of early CsA withdrawal, the
Rapamune Maintenance Regimen (RMR) study, was
conducted using the sirolimus tablet formulation [31].
The regimen comprised the administration of sirolimus
(2 mg), CsA, and steroids after transplantation, fol-
lowed by randomization to CsA withdrawal at 3 months
with sirolimus trough concentrations targeted to 20 to
30 ng/mL (immunoassay) until month 12, and 15 to
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Fig. 1. Graft survival, censored for loss to follow-up, in the Rapamune
Maintenance Regimen study.
25 ng/mL thereafter. The results of this study further
confirmed that CsA withdrawal provides benefits of im-
proved renal function and lower blood pressure. At
12 months [31], both groups showed similar patient sur-
vival and graft survival rates. Acute rejection rates were
4.2% and 9.8% for SRL-CsA-ST and SRL-ST, respec-
tively (P = 0.035). At 24 months [32], no statistically
significant differences were seen between the 2 groups
with respect to patient survival, graft survival, acute re-
jection after randomization, and discontinuations. In pa-
tients who had CsA withdrawn, serum creatinine levels
were significantly better (167 vs. 128 lmol/L, P < 0.001),
as was the slope of 1/creatinine, and systolic blood pres-
sure was significantly lower (141 vs. 134 mm Hg, P <
0.001). High-density lipoprotein (HDL) cholesterol was
significantly higher in the SRL-ST group, whereas total
cholesterol, low-density lipoprotein (LDL) cholesterol,
and triglyceride levels were not significantly different be-
tween the 2 groups. Analysis at 36 months [33] showed a
continuing beneficial trend in graft survival in the SRL-
ST group. Acute rejection rates from randomization to
month 36 were not significantly different from those in
the SRL-CsA-ST group; however, serum creatinine lev-
els were significantly better and overall renal function
improved or remained stable in SRL-ST group. Lipid pa-
rameters were similar between groups, and the cumula-
tive use of statins was comparable.
At 48 months in the RMR study [34], graft survival
censored for loss to follow-up was significantly better af-
ter CsA withdrawal, either when including death with a
functioning graft as an event (84.1% vs. 91.5%, P = 0.024,
Fig. 1), or when excluding it (90.5% vs. 96.1%, P = 0.025).
No significant differences were observed in the incidence
of death (7.9% vs. 4.7%) or biopsy-proven acute rejec-
tion after randomization (7.0% vs. 10.2%, SRL-CsA-ST
vs. SRL-ST, respectively). Figure 2 shows the 4-year acute
rejection rates based on Kaplan-Meier estimates. As illus-
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Fig. 2. Incidence of first biopsy-confirmed acute rejection in the Ra-
pamune Maintenance Regimen study.
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Fig. 3. Calculated glomerular filtration rates (Nankivell method) in the
Rapamune Maintenance Regimen study, intention to treat analysis.
trated in Figure 3, calculated GFR, including values from
discontinued patients, and setting GFR to 0 for functional
graft loss, was significantly higher (43.8 vs. 58.3 mL/min,
P < 0.001) with CsA withdrawal. Mean arterial blood
pressure (101.0 vs. 97.6 mm Hg, P = 0.046, Fig. 4) was
lower in the SRL-ST group, despite significantly less an-
tihypertensive therapy (P < 0.001). Hemoglobin (126.4
vs. 135.6 g/L, P = 0.031) was also significantly better in
patients treated with SRL-ST. Concerning fasting lipid
parameters, the only significant difference between the 2
groups was total cholesterol, which was approximately
0.5 mmol/L higher in the SRL-ST group (Fig. 5). It
should be noted that nearly all patients were on lipid-
lowering therapy: The cumulative frequency of statin
use was 76.7% versus 80.5%, and cumulative fibrate
use was 26.5% versus 27.0% in the SRL-CsA-ST versus
SRL-ST groups, respectively. The incidence of treatment-
emergent diabetes mellitus (both insulin and non–insulin-
dependent) was 7.0% in both groups. Thus, the cumu-
lative 4-year data demonstrated superior outcomes for
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Fig. 4. Mean arterial blood pressure in the Rapamune Maintenance
Regimen study, last observation carried forward (LOCF) analysis.
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Fig. 5. Serum lipid parameters at 48 months in the Rapamune Main-
tenance Regimen study.
renal function, stabilized lipid values, and the ongoing
benefit of lower blood pressure in patients receiving
SRL-ST.
DISCUSSION
The high morbidity and mortality due to CVD in
renal transplantation patients emphasizes the need to
control cardiovascular risk factors in order to improve
patient outcomes. Many of the well-recognized risk fac-
tors associated with CVD in the general population are
relevant in these patients. The number of acute rejec-
tion episodes has been found to be positively corre-
lated with post-transplantation cardiovascular risk [35,
36]. Reduced renal function is associated with increased
cardiovascular death in kidney transplantation [37]. Cal-
cineurin inhibitor-based therapies are associated with im-
paired renal function and an increase in cardiovascular
risk factors, although some of these risk factors, such as
hyperlipidemia and hypertension, may be less marked
with tacrolimus [6, 38]. Continuous treatment with cal-
cineurin inhibitors has long been associated with nephro-
toxicity leading to progressive renal dysfunction [39].
Hence, regimens that decrease or eliminate CsA are ex-
pected to show decreased nephrotoxicity. Nonetheless,
the goal of low acute rejection rates should not be com-
promised. A regimen including early withdrawal of CsA
from sirolimus-CsA-steroid therapy demonstrated at
48 months, that patients who had CsA withdrawn showed
numerically higher rates of biopsy-proven acute rejection
(P = 0.205), but significantly better calculated GFR (P <
0.001), mean arterial blood pressure (P < 0.05), and graft
survival (P = 0.025).
Data from several studies indicate that the cardiovas-
cular risks associated with sirolimus appear to be limited
to increased plasma lipid levels. Total and LDL choles-
terol have been reported to be generally elevated in trans-
plantation populations [40]. A study that assessed the
clinical relevance of the effects of sirolimus on plasma
lipids by using the Framingham risk model and lipid data
from 2 controlled trials concluded that the coronary heart
disease risks associated with the cholesterol elevations
were small compared with the baseline risks of trans-
plantation patients [41]. It is also relevant to note that
a sirolimus-coated stent has been proven to be superior
to the traditional bare-metal stent in the prevention of
restenosis after coronary angioplasty in humans [42].
CONCLUSION
Sirolimus therapy is non-nephrotoxic and does not
produce hypertension or increase the incidence of post-
transplantation insulin-dependent diabetes [26]. The hy-
perlipidemia commonly seen is usually manageable with
treatment. Moreover, the observed inhibitory effects of
sirolimus on the intimal lining of arteries may have
a potentially favorable impact with respect to CVD.
Thus, concentration-controlled sirolimus therapy initially
combined with short-term CsA therapy offers improved
efficacy outcomes along with a reduced incidence of hy-
pertension, ultimately resulting in enhanced graft sur-
vival. This emerging profile is encouraging with respect
to cardiovascular risk in renal transplant patients. Phase
3 trials are warranted to compare sirolimus-based treat-
ment directly with CsA and tacrolimus therapy, in both
de novo and late conversion renal transplantation, to fur-
ther evaluate the promise of CNI-free therapy in reducing
cardiovascular risk factors and improving renal function
and graft survival.
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